Has K V R Mohan Rao received payments from drug or device companies?

Yes. Drug and device makers reported $3,139 in general payments to K V R Mohan Rao across 156 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean K V R Mohan Rao did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about K V R Mohan Rao come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

K V R Mohan Rao

Pulmonary Disease · Springfield, MANPI 1477596799

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,419 and has fallen 93.5% since, to $158 in 2021.

$3,139in general payments, 2019–2025

Across 156 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$390
AbbVie$308
Amgen$284
Boehringer Ingelheim$277
GSK$226
AstraZeneca$191
plus $1K from 17 others

What the payments were for

Food & beverage$3,125100%
Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	24	$390
AbbVie(2 entities)	22	$308
Amgen	10	$284
Boehringer Ingelheim	11	$277
GSK	14	$226
AstraZeneca	10	$191
Lilly USA, LLC	8	$173
Insmed, Inc.	2	$168
Merck	10	$134
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$132
Grifols USA, LLC	1	$125
Novartis	5	$103
E.r. Squibb & Sons, L.L.C.	5	$100
Johnson & Johnson	6	$98
Nestle Healthcare Nutrition Inc.	3	$70
Shire North American Group Inc	3	$68
Sanofi	3	$60
Mallinckrodt Enterprises LLC	3	$57
Phadia US Inc.	2	$51
Sanofi-aventis U.S. LLC	2	$46
Teva Pharmaceuticals USA, Inc.	3	$44
Novo Nordisk	1	$24
Takeda Pharmaceuticals U.S.A., Inc.	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,139 in reported general payments places this provider in the 75th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts →

Other pulmonary disease in Springfield

Nakul RavikumarSpringfield$34K
Yaron GoldmanWorcester$843K
Sarah GrantBrookline$678K
Erik FolchBoston$543K
Bartolome CelliBoston$536K
Fernando MartinezWorcester$375K
Ana CojocaruFall River$364K
Adnan MajidBoston$351K
Adam SmithBurlington$296K
Nicholas HillBoston$293K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →